Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 2, 2010, Pages 56-62

  Horton, Robert ^a   Rocker, Graeme ^b  

^a Division of Pediatric Medicine   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Chronic obstructive pulmonary disease; Dyspnoea; Noninvasive ventilation; Palliation; Palliative care

Indexed keywords

ANXIOLYTIC AGENT; NARCOTIC ANALGESIC AGENT;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DYSPNEA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; OXYGEN THERAPY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE;

ADMINISTRATION, INHALATION; ANALGESICS, OPIOID; ANTI-ANXIETY AGENTS; DYSPNEA; HUMANS; OXYGEN INHALATION THERAPY; PALLIATIVE CARE; POSITIVE-PRESSURE RESPIRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77953839510     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328338c1c6     Document Type: Article

References (69)

1. Booth S, Silvester S, Todd C. Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers. Palliat Support Care 2003; 1:337-344.
2. Simpson AC, Rocker GM. Advanced chronic obstructive pulmonary disease: impact on informal caregivers. J Palliat Care 2008; 24:49-54.
3. Skilbeck J, Mott L, Page H, et al. Palliative care in chronic obstructive airways disease: a needs assessment. Palliat Med 1998; 12:245-254.
4. Seamark DA, Blake SD, Seamark CJ, Halpin DM. Living with severe chronic obstructive pulmonary disease (COPD): perceptions of patients and their carers. An interpretative phenomenological analysis. Palliat Med 2004;18:619-625.
5. Dyspnoea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999; 159:321-340.
6. Abernethy AP, Wheeler JL. Total dyspnoea. Curr Opin Support Palliat Care 2008; 2:110-113.
7. Rocker GM, Sinuff T, Horton R, Hernandez P. Advanced chronic obstructive pulmonary disease: innovative approaches to palliation. J Palliat Med 2007; 10:783-797.
8. Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008; 177:912-927.
9. Simpson AC, Rocker GM. Advanced chronic obstructive pulmonary disease: rethinking models of care. Q J Med 2008; 101:697-704.
10. Smith J, Albert P, Bertella E, et al. Qualitative aspects of breathlessness in health and disease. Thorax 2009; 64:713-718.
11. Lansing RW, Gracely RH, Banzett RB. The multiple dimensions of dyspnoea: review and hypotheses. Respir Physiol Neurobiol 2009; 167:53-60.
12. von Leupoldt A, Sommer T, Kegat S, et al. Dyspnoea and pain share emotionrelated brain network. Neuroimage 2009; 48:200-206.
13. Schon D, Dahme B, von Leupoldt A. Associations between the perception of dyspnoea, pain, and negative affect. Psychophysiology 2008; 45:1064-1067.
14. Williams M, Cafarella P, Olds T, et al. The language of breathlessness differentiates between patients with COPD and age-matched adults. Chest 2008; 134:489-496.
15. von Leupoldt A, Sommer T, Kegat S, et al. The unpleasantness of perceived dyspnoea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med 2008; 177:1026-1032.
16. Schon D, Rosenkranz M, Regelsberger J, et al. Reduced perception of dyspnoea and pain after right insular cortex lesions. Am J Respir Crit Care Med 2008; 178:1173-1179.
17. Peiffer C, Costes N, Herve P, Garcia-Larrea L. Relief of dyspnoea involves a characteristic brain activation and a specific quality of sensation. Am J Respir Crit Care Med 2008; 177:440-449.
18. Pattinson KT, Mitsis GD, Harvey AK, et al. Determination of the human brainstem respiratory control network and its cortical connections in vivo using functional and structural imaging. Neuroimage 2009; 44:295-305.
19. Peiffer C. Dyspnoea and emotion: what can we learn from functional brain imaging? Am J Respir Crit Care Med 2008; 177:937-939.
20. Evans KC, Banzett RB, Adams L, et al. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 2002; 88:1500-1511.
21. Pattinson KT, Governo RJ, MacIntosh BJ, et al. Opioids depress cortical centers responsible for the volitional control of respiration. J Neurosci 2009; 29:8177-8186.
22. Bausewein C, Booth S, Gysels M, Higginson I. Nonpharmacological interventions for breathlessness in advanced stages of malignant and nonmalignant diseases. Cochrane Database Syst Rev 2008:CD005623.
23. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555.
24. Abramson MJ, Crockett AJ, Frith PA, McDonald CF. COPDX: an update of guidelines for the management of chronic obstructive pulmonary disease with a review of recent evidence. Med J Aust 2006; 184:342-345.
25. O'Donnell DE, Aaron S, Bourbeau J, et al. State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can Respir J 2004; 11 (Suppl B):7B-59B.
26. Rocker G, Horton R, Currow D, et al. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax 2009; 64:910-915.
27. Currow DC, Kenny B, McDonald C, et al. Multisite open label dose ranging study to determine the minimum effective dose of sustained release morphine (SRM) for reducing refractory breathlessness. 11th Congress of the European Association of Palliative Care Abstracts; May 7-10 2009; Vienna Austria: Eur J Pall Care Supp. 2009; p. 39.
28. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327:523-528.
29. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157 (6 Pt 1):1877-1880.
30. Eiser N, Denman WT, West C, Luce P. Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the 'pink puffer' syndrome. Eur Respir J 1991; 4:926-931.
31. Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breathlessness in 'pink puffers'. Br Med J (Clin Res Ed) 1983; 286:675-677.
32. Woodcock AA, Gross ER, Gellert A, et al. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981; 305:1611-1616.
33. Woodcock AA, Johnson MA, Geddes DM. Breathlessness, alcohol, and opiates. N Engl J Med 1982; 306:1363-1364.
34. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57:939-944.
35. Sitte T, Bausewein C. Intranasal fentanyl for episodic breathlessness. J Pain Symptom Manage 2008; 36:e3-e6.
36. Coyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnoea. J Pain Symptom Manage 2002; 23:157-160.
37. Krajnik M, Podolec Z, Siekierka M, et al. Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain Symptom Manage 2009; 38:747-757.
38. Mather LE, Woodhouse A, Ward ME, et al. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. Br J Clin Pharmacol 1998; 46:37-43.
39. Schultheis CP. Nebulized fentanyl provides subjective improvements for patients with dyspnoea. Oncol Nurs Forum 2005; 32:15; author reply.
40. Smith TJ, Coyne P, French W, et al. Failure to accrue to a study of nebulized fentanyl for dyspnoea: lessons learned. J Palliat Med 2009; 12:771-772.
41. Guyatt GH, Heyting A, Jaeschke R, et al. N-of-1 randomized trials for investigating new drugs. Control Clin Trials 1990; 11:88-100. (Pubitemid 20136183)
42. Clinical Trials.gov. Effect of inhaled nebulized fentanyl on exertional dyspnoea and exercise tolerance in patients with moderate-to-severe COPD. National Library of Medicine; 2009.
43. de Leon-Casasola OA. Current developments in opioid therapy for management of cancer pain. Clin J Pain 2008; 24 (Suppl 10):S3-S7.
44. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009; 25:2877-2885.
45. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009; 25:2805-2815.
46. Fentanyl buccal tablet (Fentora) for breakthrough pain. Med Lett Drugs Ther 2007; 49:78-79.
47. Hill L, Schug SA. Recent advances in the pharmaceutical management of pain. Expert Rev Clin Pharmacol 2009; 2:543-557.
48. Bailey PH. The dyspnoea-anxiety-dyspnoea cycle: COPD patients'stories of breathlessness - 'it's scary/when you can't breathe'. Qual Health Res 2004; 14:760-778.
49. Benitez-Rosario MA, Martin AS, Feria M. Oral transmucosal fentanyl citrate in the management of dyspnoea crises in cancer patients. J Pain Symptom Manage 2005; 30:395-397.
50. Zelman DC, Smith MY, Hoffman D, et al. Acceptable, manageable, and tolerable days: patient daily goals for medication management of persistent pain. J Pain Symptom Manage 2004; 28:474-487.
51. 2 ventilatory responsiveness in humans. Pulm Pharmacol Ther 2002; 15:363-368.
52. Moosavi SH, Binks AP, Lansing RW, et al. Effect of inhaled furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol 2007; 156:1-8.
53. Nishino T, Ide T, Sudo T, Sato J. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnoea. Am J Respir Crit Care Med 2000; 161:1963-1967.
54. Ong KC, Kor AC, Chong WF, et al. Effects of inhaled furosemide on exertional dyspnoea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169:1028-1033.
55. Jensen D, Amjadi K, Harris-McAllister V, et al. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax 2008; 63:606-613.
56. Man GC, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dyspnoea in patients with chronic obstructive pulmonary disease. Chest 1986; 90:832-836.
57. Stege G, Heijdra YF, van den Elshout FJ, et al. Temazepam 10mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respir Med 2009; 104:518-524.
58. Simon ST, Higgins IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and nonmalignant diseases in adults. Cochrane Database Syst Rev. 2010; Issue 1. Art. No.: CD007354. DOI: 10.1002/14651858.CD007354.pub2.
59. Smoller JW, Pollack MH, Otto MW, et al. Panic anxiety, dyspnoea, and respiratory disease. Theoretical and clinical considerations. Am J Respir Crit Care Med 1996; 154:6-17.
60. Kacmarek RM. Should noninvasive ventilation be used with the do-notintubate patient? Respir Care 2009; 54:223-229; discussion 229-231.
61. Nava S, Cuomo A, Maugeri FS. Noninvasive ventilation and dyspnoea in palliative medicine. Chest 2006; 129:1391-1392.
62. Tsolaki V, Pastaka C, Karetsi E, et al. One-year noninvasive ventilation in chronic hypercapnic COPD: effect on quality of life. Respir Med 2008; 102:904-911.
63. Duiverman ML, Wempe JB, Bladder G, et al. Nocturnal noninvasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax 2008; 63:1052-1057.
64. Meduri GU, Fox RC, Abou-Shala N, et al. Noninvasive mechanical ventilation via face mask in patients with acute respiratory failure who refused endotracheal intubation. Crit Care Med 1994; 22:1584-1590.
65. Benhamou D, Girault C, Faure C, et al. Nasal mask ventilation in acute respiratory failure. Experience in elderly patients. Chest 1992; 102:912-917.
66. Sinuff T, Cook DJ, Keenan SP, et al. Noninvasive ventilation for acute respiratory failure near the end of life. Crit Care Med 2008; 36:789-794.
67. Goodridge D, Marciniuk DD, Brooks D, et al. End-of-life care for persons with advanced chronic obstructive pulmonary disease: report of a national interdisciplinary consensus meeting. Can Respir J 2009; 16:e51-e53.
68. Booth S, Farquhar M, Gysels M, et al. The impact of a breathlessness intervention service (BIS) on the lives of patients with intractable dyspnoea: a qualitative phase 1 study. Palliat Support Care 2006; 4:287-293.
69. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504.